Related Experiment Video
Updated: Oct 7, 2025
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Biomarkers with Potential Predictive Value for Cardiotoxicity in Anticancer Treatments
1The Key Laboratory of Cardiovascular Remodeling and Function Research of Chinese Ministry of Education and Chinese Ministry of Health, The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Department of Cardiology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, China.
Anticancer treatments improve survival but risk cardiotoxicity. New biomarkers show promise for early detection of cardiovascular complications, aiding timely treatment adjustments.
Area of Science:
- Oncology
- Cardiology
- Biomarker Discovery
Background:
- Anticancer treatments have advanced, improving patient survival.
- Cardiotoxicity is a significant long-term side effect of cancer therapies.
- Current diagnostic methods lack high sensitivity and specificity for predicting treatment-induced cardiotoxicity.
Purpose of the Study:
- To review the mechanisms of anticancer treatment-induced cardiotoxicity.
- To explore the potential of novel cardiovascular biomarkers for early detection.
- To discuss the clinical value of biomarkers and echocardiography in managing cardiotoxicity.
Main Methods:
- Review of current literature on cardiotoxicity mechanisms and biomarkers.
- Analysis of established biomarkers like cardiac troponin T/I and BNP/NT-proBNP.
- Evaluation of emerging biomarkers including sST2, MPO, GDF-15, Galectin-3, and Endothelin-1.
Main Results:
- Inflammation, fibrosis, and oxidative stress are key mechanisms in cardiotoxicity.
- Established biomarkers (Troponin, BNP/NT-proBNP) are used clinically.
- Emerging biomarkers show potential for earlier and more accurate detection of cardiovascular dysfunction.
Conclusions:
- Early detection of cardiotoxicity is crucial for treatment adjustment and prognosis.
- Novel biomarkers offer promise beyond current clinical standards.
- Further large-scale studies are needed to validate new biomarkers and develop cost-effective detection methods.
More Related Videos
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
08:14MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
Related Concept Videos
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...